blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1528933

EP1528933 - PHARMACEUTICAL ANTI-TNF-ALPHA ANTIBODY FORMULATION [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  22.09.2017
Database last updated on 03.10.2024
Most recent event   Tooltip04.05.2018Lapse of the patent in a contracting state
New state(s): CY		published on 06.06.2018  [2018/23]
Applicant(s)For all designated states
AbbVie Biotechnology Ltd
Clarendon House
2, Church Street
HM 11 Hamilton / BM
[2014/01]
Former [2012/18]For all designated states
Abbott Biotechnology Ltd.
Clarendon House, 2 Church Street
HM 11 Hamilton / BM
Former [2005/19]For all designated states
Abbott Biotechnology Ltd.
Clarendon House, 2 Church Street
HM 11 Hamilton / BM
Inventor(s)01 / KRAUSE, Hans-Juergen
Marie-Curie-Weg 1
68647 Biblis / DE
02 / BAUST, Lisa
Goethestr. 15a
67063 Ludwigshafen / DE
03 / DICKES, Michael
Schafergasse 58
67127 Rodersheim-Gronau / DE
 [2006/21]
Former [2005/19]01 / KRAUSE, Hans-Juergen
Dieselstrasse 33
67551 Worms / DE
02 / BAUST, Lisa
Stamitzstrasse 8
68167 Mannheim / DE
03 / DICKES, Michael
Schafergasse 58
67127 Rodersheim-Gronau / DE
Representative(s)König, Gregor Sebastian, et al
König-Szynka-Tilmann-von Renesse
Patentanwälte Partnerschaft mbB
Postfach 11 09 46
40509 Düsseldorf / DE
[2014/08]
Former [2012/18]Reitstötter - Kinzebach
Patentanwälte Sternwartstrasse 4
81679 München / DE
Former [2009/39]Reitstötter - Kinzebach
Patentanwälte Sternwartstrasse 4
81679 München / DE
Former [2005/19]Reitstötter - Kinzebach & Partner (GbR)
Patentanwälte Sternwartstrasse 4
81679 München / DE
Application number, filing date03748439.115.08.2003
[2005/19]
WO2003IB04502
Priority number, dateUS2002022214016.08.2002         Original published format: US 222140
[2005/19]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2004016286
Date:26.02.2004
Language:EN
[2004/09]
Type: A2 Application without search report 
No.:EP1528933
Date:11.05.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 26.02.2004 takes the place of the publication of the European patent application.
[2005/19]
Type: B1 Patent specification 
No.:EP1528933
Date:02.05.2012
Language:EN
[2012/18]
Search report(s)International search report - published on:EP22.07.2004
ClassificationIPC:A61K39/395, A61K9/19, A61K47/26
[2005/19]
CPC:
A61K39/39591 (EP,US); A61K39/395 (KR); A61K39/3955 (US);
A61K47/02 (US); A61K47/10 (US); A61K47/12 (US);
A61K47/22 (US); A61K47/26 (EP,KR,US); A61K9/0019 (EP,US);
A61K9/19 (EP,US); A61P1/00 (EP); A61P1/02 (EP);
A61P1/04 (EP); A61P1/16 (EP); A61P1/18 (EP);
A61P11/00 (EP); A61P11/06 (EP); A61P13/12 (EP);
A61P15/00 (EP); A61P17/00 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P19/04 (EP); A61P19/06 (EP);
A61P19/08 (EP); A61P25/02 (EP); A61P25/04 (EP);
A61P27/02 (EP); A61P29/00 (EP); A61P3/04 (EP);
A61P3/10 (EP); A61P31/00 (EP); A61P31/04 (EP);
A61P31/12 (EP); A61P31/18 (EP); A61P33/06 (EP);
A61P35/00 (EP); A61P37/00 (EP); A61P37/02 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP);
A61P7/00 (EP); A61P9/00 (EP); A61P9/04 (EP);
A61P9/10 (EP); C07K16/241 (EP,US); A61K2039/505 (US);
C07K2317/21 (EP,US); C07K2317/76 (EP,US); C07K2317/92 (US);
C07K2317/94 (EP,US); Y02A50/30 (US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/19]
TitleGerman:PHARMEZEUTISCHE ANTI-TNF-ALPHA ANTIKÖRPER FORMULIERUNG[2005/19]
English:PHARMACEUTICAL ANTI-TNF-ALPHA ANTIBODY FORMULATION[2005/19]
French:FORMULATION PHARMACEUTIQUE D'ANTICORPS ANTI-TNF-ALPHA[2005/19]
Entry into regional phase11.02.2005National basic fee paid 
11.02.2005Designation fee(s) paid 
11.02.2005Examination fee paid 
Examination procedure15.03.2004Request for preliminary examination filed
International Preliminary Examining Authority: EP
11.02.2005Examination requested  [2005/19]
15.09.2006Despatch of a communication from the examining division (Time limit: M06)
26.03.2007Reply to a communication from the examining division
05.08.2008Despatch of a communication from the examining division (Time limit: M09)
15.05.2009Reply to a communication from the examining division
12.11.2010Date of oral proceedings
10.12.2010Minutes of oral proceedings despatched
20.12.2010Despatch of communication that the application is refused, reason: substantive examination {1}
26.08.2011Observations by third parties
25.01.2012Communication of intention to grant the patent
16.02.2012Fee for grant paid
16.02.2012Fee for publishing/printing paid
11.07.2016Observations by third parties
Appeal following examination25.02.2011Appeal received
29.04.2011Statement of grounds filed
23.05.2011Interlocutory revision of appeal
Divisional application(s)EP10182598.2  / EP2363144
EP10182610.5  / EP2359856
EP10182619.6  / EP2361637
EP10182625.3  / EP2363145
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.09.2006
Opposition(s)Opponent(s)01  01.02.2013  14.02.2013  ADMISSIBLE
Storz, Dr. Ulrich
c/o Michalski Hüttermann Patentanwälte mbB
Speditionstrasse 21
40221 Düsseldorf / DE
 02  01.02.2013  18.02.2013  ADMISSIBLE
Alfred E. Tiefenbacher (GmbH & Co. KG)
Van-der-Smissen-Straße 1
22767 Hamburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 03  04.02.2013  14.02.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Pohlman, Sandra M.
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München / DE
 04  01.02.2013  14.02.2013  ADMISSIBLE
Bird, William Edward
Patentive
Prinz-Georg-Strasse 91
40479 Düsseldorf / DE
 [N/P]
Former [2016/11]
Opponent(s)01  01.02.2013  14.02.2013  ADMISSIBLE
Storz, Dr. Ulrich
c/o Michalski Hüttermann Patentanwälte mbB
Speditionstrasse 21
40221 Düsseldorf / DE
 02  01.02.2013  18.02.2013  ADMISSIBLE
Alfred E. Tiefenbacher (GmbH & Co. KG)
Van-der-Smissen-Straße 1
22767 Hamburg / DE
Opponent's representative
Hamm & Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 03  04.02.2013  14.02.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Pohlman, Sandra M.
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München / DE
 04  01.02.2013  14.02.2013  ADMISSIBLE
Bird, William Edward
Patentive
Prinz-Georg-Strasse 91
40479 Düsseldorf / DE
Former [2014/41]
Opponent(s)01  01.02.2013  14.02.2013  ADMISSIBLE
Storz, Dr. Ulrich
c/o Michalski Hüttermann Patentanwälte mbB
Speditionstrasse 21
40221 Düsseldorf / DE
 02  01.02.2013  18.02.2013  ADMISSIBLE
Alfred E. Tiefenbacher (GmbH & Co. KG)
Van-der-Smissen-Straße 1
22767 Hamburg / DE
Opponent's representative
Wittkopp, Alexander
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 03  04.02.2013  14.02.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Pohlman, Sandra M.
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München / DE
 04  01.02.2013  14.02.2013  ADMISSIBLE
Bird, William Edward
Patentive
Prinz-Georg-Strasse 91
40479 Düsseldorf / DE
Former [2013/21]
Opponent(s)01  01.02.2013  14.02.2013  ADMISSIBLE
Storz, Dr. Ulrich
c/o Michalski Hüttermann Patentanwälte
Speditionstrasse 21
40221 Düsseldorf / DE
 02  01.02.2013  18.02.2013  ADMISSIBLE
Alfred E. Tiefenbacher (GmbH & Co. KG)
Van-der-Smissen-Straße 1
22767 Hamburg / DE
Opponent's representative
Wittkopp, Alexander
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 03  04.02.2013  14.02.2013  ADMISSIBLE
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Pohlman, Sandra M.
Df-mp Fünf Höfe Theatinerstraße 16
80333 München / DE
 04  01.02.2013  14.02.2013  ADMISSIBLE
Bird, William Edward
Patentive
Prinz-Georg-Strasse 91
40479 Düsseldorf / DE
Former [2013/11]
Opponent(s)01  01.02.2013   
Storz, Dr. Ulrich
c/o Michalski Hüttermann Patentanwälte
Speditionstrasse 21
40221 Düsseldorf / DE
 02  01.02.2013   
Alfred E. Tiefenbacher (GmbH & Co. KG)
Van-der-Smissen-Straße 1
22767 Hamburg / DE
Opponent's representative
Wittkopp, Alexander
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 03  04.02.2013   
Teva Pharmaceutical Industries LTD.
5 Basel Street
Petah Tiqva 49131 / IL
Opponent's representative
Greiner, Elisabeth
Df-mp
Fünf Höfe
Theatinerstraße 16
DE-80333 München / DE
 04  01.02.2013    ADMISSIBLE
Bird, William Edward
Patentive
Prinz-Georg-Strasse 91
40479 Düsseldorf / DE
08.03.2013Invitation to proprietor to file observations on the notice of opposition
17.01.2014Reply of patent proprietor to notice(s) of opposition
08.09.2015Date of oral proceedings
13.10.2015Despatch of minutes of oral proceedings
13.10.2015Despatch of communication that the patent will be revoked
21.08.2017Legal effect of revocation of patent [2017/43]
Appeal following opposition17.12.2015Appeal received No.  T2334/15
23.02.2016Statement of grounds filed
14.09.2016Invitation to file observations in an appeal (Time limit: M04) [2016/38]
24.01.2017Date of receipt of observations in an appeal [2017/04]
21.08.2017Result of appeal procedure: appeal of the proprietor withdrawn
Fees paidRenewal fee
08.08.2005Renewal fee patent year 03
07.08.2006Renewal fee patent year 04
03.08.2007Renewal fee patent year 05
27.03.2008Renewal fee patent year 06
07.08.2009Renewal fee patent year 07
06.08.2010Renewal fee patent year 08
08.08.2011Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCH02.05.2012
LI02.05.2012
CY15.08.2017
[2018/23]
Former [2017/51]CH02.05.2012
LI02.05.2012
Cited inInternational search[X]WO9704801  (GENENTECH INC [US]);
 [XY]WO9856418  (GENENTECH INC [US]);
 [X]US5945098  (SARNO MARIA ERLINDA C [US], et al);
 [XY]US6024938  (CORBO DIANE C [US], et al);
 [DY]US6090382  (SALFELD JOCHEN G [US], et al);
 [X]US6171586  (LAM XANTHE M [US], et al);
 [XY]WO0147554  (CHUGAI PHARMACEUTICAL CO LTD [JP], et al);
 [XY]EP1174148  (YAMANOUCHI PHARMA CO LTD [JP]);
 [Y]WO0212502  (CENTOCOR INC [US]);
 EP1254666  [ ] (CHUGAI PHARMACEUTICAL CO LTD [JP]);
ExaminationWO9729131
    - CARPENTER-JF ET AL., "Rational design of stable lyophilized protein formulations: some practical advice", PHARM RES, (199708), vol. 14, no. 8, doi:doi:10.1023/A:1012180707283, page 969-75, XP002303280

DOI:   http://dx.doi.org/10.1023/A:1012180707283
    - WANG-W, "Instability, stabilization, and formulation of liquid protein pharmaceuticals", INT J PHARM, (19990820), vol. 185, no. 2, page 129-88, XP002616539

DOI:   http://dx.doi.org/10.1016/S0378-5173(99)00152-0
    - AKERS-MJ ET AL., Development and Manufacture of Protein Pharmaceuticals (Pharmaceutical Biotechnology): chapter 2 Formulation Development of Protein Dosage Forms, NEW YORK, KLUWER ACADEMIC/PLENUM PUBLISHER, (20020630), XP001537612
    - BARRERA P ET AL, "Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.", ANNALS OF THE RHEUMATIC DISEASES JUL 2001 LNKD- PUBMED:11406520, (200107), vol. 60, no. 7, doi:doi:10.1136/ard.60.7.660, ISSN 0003-4967, pages 660 - 669, XP009131336

DOI:   http://dx.doi.org/10.1136/ard.60.7.660
    - HARRIS REED J ET AL, "Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies", DRUG DEVELOPMENT RESEARCH, (200403), vol. 61, no. 3, doi:doi:10.1002/ddr.10344, ISSN 0272-4391, pages 137 - 154, XP002649544

DOI:   http://dx.doi.org/10.1002/ddr.10344
    - WANG WEI ET AL, "Antibody structure, instability, and formulation.", JOURNAL OF PHARMACEUTICAL SCIENCES JAN 2007 LNKD- PUBMED:16998873, (200701), vol. 96, no. 1, doi:doi:10.1002/jps.20727, ISSN 0022-3549, pages 1 - 26, XP009084505

DOI:   http://dx.doi.org/10.1002/jps.20727
by applicantEP0218868
 EP0230574
 EP0374510
 WO9104054
 EP0453898
 WO9203145
 WO9211383
 EP0186833
 WO9216553
 WO9216221
 WO9217583
 WO9311793
 US5231024
 EP0260610
 WO9319751
 EP0585705
 WO9408609
 EP0614984
 WO9420139
 WO9520978
 US6015557
 US6090382
 WO0050079
 US6177077
 US2001004456
 US6258562
 WO0149321
 US2001016195
 US2001026801
 US6379666
 US6419934
 US6419944
 US6423321
 US6428787
 US20020397275
otherUS6090382
 US6258562
    - REGISTRY, Chemical Abstracts Service, Columbus, Ohio, US, Database accession no. 331731-18-1, URL: STN, XP055297934
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.